These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8257596)

  • 1. Pulmonary surfactant inhibits interleukin-2-induced proliferation and the generation of lymphokine-activated killer cells.
    Roth MD; Pinto M; Golub SH; Shau H
    Am J Respir Cell Mol Biol; 1993 Dec; 9(6):652-8. PubMed ID: 8257596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of lymphokine-activated killer cells by human pulmonary macrophages: discordance between up-regulation of the beta chain (p75) of the interleukin-2 receptor on CD56+ cells and limited response to interleukin-2.
    Yarbrough WC; Wilkes DS; Weissler JC
    Am J Respir Cell Mol Biol; 1994 Feb; 10(2):184-91. PubMed ID: 7509162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of lymphokine-activated killer cell induction by human recombinant IL-1 receptor antagonist. Obligate paracrine pathway of IL-1 during lymphokine-activated killer cell induction.
    Fujiwara T; Grimm EA
    J Immunol; 1992 May; 148(9):2941-6. PubMed ID: 1374105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity.
    Galandrini R; Albi N; Zarcone D; Grossi CE; Velardi A
    Eur J Immunol; 1992 Aug; 22(8):2047-53. PubMed ID: 1379184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures.
    Spits H; Yssel H; Paliard X; Kastelein R; Figdor C; de Vries JE
    J Immunol; 1988 Jul; 141(1):29-36. PubMed ID: 2454260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that interleukin-4 suppression of lymphokine-activated killer cell induction is mediated through monocytes.
    Brooks B; Parry H; Lawry J; Rees R
    Immunology; 1992 Feb; 75(2):343-8. PubMed ID: 1551696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
    Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
    Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of lymphokine-activated killer activity in T-replete and T-cell-depleted human bone marrow by interleukin 4.
    Drobyski WR; LeFever AV; Truitt RL
    Exp Hematol; 1991 Oct; 19(9):950-7. PubMed ID: 1716592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human pulmonary natural killer (NK) cells exhibit limited lymphokine-activated killer (LAK) activity.
    Yarbrough WC; Weissler JC
    Am J Respir Cell Mol Biol; 1989 Oct; 1(4):305-11. PubMed ID: 2483121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta.
    Smyth MJ; Strobl SL; Young HA; Ortaldo JR; Ochoa AC
    J Immunol; 1991 May; 146(10):3289-97. PubMed ID: 1827481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
    Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
    Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2.
    Horton SA; Oldham RK; Yannelli JR
    Cancer Res; 1990 Mar; 50(6):1686-92. PubMed ID: 2306722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
    Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
    Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of lymphokine release and cytolytic activities by activating peripheral blood lymphocytes via CD2.
    Valentin H; Groux H; Gelin C; Chretien I; Bernard A
    J Immunol; 1990 Feb; 144(3):875-82. PubMed ID: 1967277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.
    Naume B; Gately M; Espevik T
    J Immunol; 1992 Apr; 148(8):2429-36. PubMed ID: 1373169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
    Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
    J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant interleukin 4 (RIL4) inhibits interleukin 2-induced activation of peripheral blood lymphocytes.
    Han X; Itoh K; Balch CM; Pellis NR
    Lymphokine Res; 1988; 7(3):227-35. PubMed ID: 3263554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.